You searched for "DMO"
100% Optical and Optrafair organisers join forces
From now on there will be one major annual exhibition, 100% Optical at London’s ExCeL exhibition centre, which has full industry support from the FMO and other major optical bodies.Jason Higginbotham launches independent consulting business FYEye Ltd.
Former Director of Medical & Education at Birmingham Optical Group, Jason Higginbotham, has launched an independent consulting business, FYEye Ltd.
Retinitis pigmentosa (RP) associated cystoid macular oedema (CMO)
This is a review article from two units in the UK and Australia, highlighting the supporting evidence of possible pathogenesis and treatment modalities of CMO in RP. The authors proposed that the likely mechanisms for RP-CMO involved the breakdown of...Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...Horus Pharma to distribute intravitreal implant ILUVIEN® in France
Intravitreal implant ILUVIEN, developed by Alimera Sciences, is now available in France, distributor Horus Pharma has announced. ILUVIEN is aimed at patients with vision impairment associated with chronic Diabetic Macular Edema (DME), who have not responded well to other available...NICE drugs: an update on what’s good to go
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...
Does intravitreal bevacizumab help in diabetic retinopathy related vitreous haemorrhage?
This retrospective, interventional case series, aimed to assess the effectiveness of intravitreal bevacizumab (IVB) in vitreous haemorrhage secondary to proliferative diabetic retinopathy. The primary outcome was the rate of vitrectomy (PPV) after IVB, with secondary outcomes the number of IVB...
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
Risk calculation variability over time in OHT
In this study the authors aimed to assess the variability of the well documented risk model from the Ocular Hypertension Treatment Study (OHTS) that identified higher intraocular pressure (IOP), older age, lower central corneal thickness (CCT), greater vertical cup-to-disc ratio...
